Key facts
- It has raised $3.5M.
- Notable investors include European Commission, Business Finland, European Regional Development Fund (Brandenburg), Nordic Mentor Network For Entrepreneurship, Stephen Industries — 12 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 12 names
- ·Watchlist + deal alerts for StemSight
- ·The full record, as it builds
Funding rounds
No funding rounds for StemSight are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About StemSight
Developer of an off-the-shelf cell therapy platform designed to treat blindness. The company's platform treats cells based on induced pluripotent stem cells (iPSCs) and biomaterials, and it aims to enter the market with first-in-class therapy for a rare disease, limbal stem cell deficiency, later expanding to major forms of corneal blindness, enabling patients with corneal blindness to regain their vision.
- Sector
- Healthcare
- HQ
- Tampere, Finland
- Employees
- 13
- Website
- stemsight.fi/
- Ownership
- Privately Held (backing)
StemSight doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in StemSight shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on StemSight in its N-PORT filings yet. We sweep new filings monthly.